Anosmia, the loss of the sense of smell, is one of the main neurological manifestations of
COVID-19. Although the SARS-CoV-2 virus targets the nasal olfactory epithelium, current …

Numerous pathogens can infect the olfactory tract, yet the pandemic caused by SARS-CoV-
2 has strongly emphasized the importance of the olfactory mucosa as an immune barrier …

Introduction Mild cognitive impairment (MCI) is a prodromal stage to dementia, affecting up
to 20% of the aging population worldwide. Patients with MCI have an annual conversion rate …

During the first waves of the coronavirus disease 2019 (COVID-19) pandemic caused by
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, olfactory …

COVID-associated anosmia often is fulminant and complete but can recover within as little
as 5–7 days (2). Mechanistic models have to account for these two facts. The rapid time …

Introduction Olfactory dysfunction (OD) is a typical symptom of chronic rhinosinusitis (CRS),
which adversely affects the patient's quality of life and results in mood depression. Studies …

Neuroinvasion of SARS-CoV-2 is a matter of debate [5, 8, 10]. While some animal models (in
particular genetically modified ones) revealed a consistent and fatal neuroinvasion of SARS …

The olfactory mucosa is a component of the nasal airway that mediates the sense of smell.
Recent studies point to an important role for the olfactory mucosa as a barrier to both …

Animal models that can replicate clinical and pathologic features of severe human
coronavirus infections have been instrumental in the development of novel vaccines and …

Among the numerous long COVID symptoms, olfactory dysfunction persists in∼ 10% of
patients suffering from SARS-CoV-2 induced anosmia. Among the few potential therapies …